The aim of this review is to discuss the current understanding of HSP90′s role in the development of pulmonary fibrosis, the current proteomic understanding of IPF, evaluate available preclinical data and describe how inhibition of HSP90 could be a therapeutical target for patients with IPF. Here, HSP90AA1 is linked to idiopathic pulmonary fibrosis.